🔥Telegram İfşa

Congratulations to Korify Capital's portfolio company Gameto on its $44M Series C to advance women’s healthcare. These are the type of breakthroughs we invest in – with a focus on improving quality of life. bloomberg.com/news/articles/…

Sweden is the only European market adapting to the US model for growth IPOs. 🚀 With Apeiron Investment Group , we’re bringing Infinitas portfolio companies like HausVorteil to Stockholm — the first of many to come. cnbc.com/2025/08/28/inf…

Christian Angermayer and I recently spoke to Carsten Puschmann at @Business Punk about European capital markets. Too many of Europe’s best companies still choose to go public in the US. This is not happening because Europe lacks talent, ideas, or capital, but because our capital

heavenly. divine. ethereal.

At infinitas, we are very bullish that #biotech (IPOs) and especially #psychedelics will bounce back big time over the next 18 months - buying more $atai !

🚀🍄$ATAI + Beckley Psytech just reported positive Phase 2a data with BPL-003 in TRD. This feels paradigm-shifting. Let’s unpack👇

Encouraging news from Alto Neuroscience: the U.S. FDA has granted Fast Track designation to ALTO-101 for treating cognitive impairment in schizophrenia (CIAS). No approved therapies exist today—together, we’re working to change that. Learn more here: bit.ly/3IMDAll #FastTrack

Stay tuned...

At Infinitas, we don’t just invest in ideas — we invest in how people live. linkedin.com/pulse/investin…

[FOR INVESTORS AND MEDIA] The FDA has granted Breakthrough Therapy designation to BPL-003 for treatment-resistant depression. This milestone validates our strong Phase 2b data and accelerates our path forwards to Phase 3. beckleypsytech.com/posts/atai-lif…

$ATAI just delivered — FDA Breakthrough Therapy Designation + $130M financing. This is why I’m buying more. Bullish on mental health biotech, #Psychedelics and the @atai_life vision. 🍄🍄🍄 ir.atai.com/news-releases/…

I added $ANRO to my portfolio at around $2.75 a share. Like psychedelic drug development companies, $ANRO is working with a de-risked drug that shows potential paradigm-shifting efficacy in TRD. Unlike psychedelics, ALTO-207, if data is replicated, will be approved as a take home

How Psychedelic Mushrooms Evolved Their Magic - The New York Times nytimes.com/2025/10/18/sci…

Biotech is turning. $ANRO raised $50M after FDA feedback to accelerate ALTO-207 in TRD. Stock up ~90% today. $ATAI raised $130M at market after FDA breakthrough for 5-MeO TRD. Stock up 400% YTD. Market is finally waking up.

Adding to my post from yesterday — here’s why the stars are aligning for biotech. We’re seeing clear signs that the narrative is shifting: ✅ The $XBI is up 50%, but valuations remain well below previous cycle highs, while most other sectors are already trading at peak

The ultimate luxury isn’t a thing — it’s time. Time to slow down. To explore. To enjoy moments that don’t need a schedule. What I love about Azuro’s approach is that it captures exactly that — the freedom to live beautifully, without the weight of ownership. A model that

🚀 Exciting week ahead… Big things are happening over the next few days — milestones we’ve been working toward for a long time. Grateful for the incredible people involved so far — and looking forward to sharing more very soon. Stay tuned. ✨

Very happy to announce that HausVorteil is going public in Germany tomorrow! As a family office, Infinitas Capital Group has the flexibility to follow its capital into the listing. We are seeing substantial runway for further value creation, supported by the company’s highly scalable

HausVorteil, which specializes in recapitalization and brokerage solutions in Germany, is going public in Munich tomorrow! And as a family office, we have the flexibility to follow our capital into the listing. pehub.com/infinitas-capi…